CIMT 2022: Report on the 19th Annual Meeting of the Association for Cancer Immunotherapy

References

• Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E, Wunderlich JR, Mixon A, Farid S, Dudley ME, et al. PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. J Clin Invest [Internet]. 2014;124(5):1–11. doi:10.1172/JCI73639.
   Web of Science ®Google Scholar
• Gros A, Parkhurst MR, Tran E, Pasetto A, Robbins PF, Ilyas S, Prickett TD, Gartner JJ, Crystal JS, Roberts IM, et al. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat Med [Internet]. 2016;22(4):433–38. doi:10.1038/nm.4051.
   PubMed Web of Science ®Google Scholar
• Gorris MAJ, van der Woude LL, Kroeze LI, Bol K, Verrijp K, Amir AL, Meek J, Textor J, Figdor CG, de Vries IJM. Paired primary and metastatic lesions of patients with ipilimumab-treated melanoma: high variation in lymphocyte infiltration and HLA-ABC expression whereas tumor mutational load is similar and correlates with clinical outcome. J Immunother Cancer [Internet]. 2022;10. http://www.ncbi.nlm.nih.gov/pubmed/35550553.
   PubMed Web of Science ®Google Scholar
• DuPage M, Dooley AL, Jacks T. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat Protoc [Internet]. 2009;4(7):1064–72. doi:10.1038/nprot.2009.95.
   PubMed Web of Science ®Google Scholar
• DuPage M, Cheung AF, Mazumdar C, Winslow MM, Bronson R, Schmidt LM, Crowley D, Chen J, Jacks T. Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression. Cancer Cell [Internet]. 2011;19(1):72–85. doi:10.1016/j.ccr.2010.11.011.
   PubMed Web of Science ®Google Scholar
• Burger ML, Cruz AM, Crossland GE, Gaglia G, Ritch CC, Blatt SE, Bhutkar A, Canner D, Kienka T, Tavana SZ, et al. Antigen dominance hierarchies shape TCF1+ progenitor CD8 T cell phenotypes in tumors. Cell [Internet]. 2021;184(19):4996–5014.e26. doi:10.1016/j.cell.2021.08.020.
   Google Scholar
• Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, Lieb DJ, Chen JH, Frederick DT, Barzily-Rokni M, et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell [Internet]. 2019;176(1–2):404. doi:10.1016/j.cell.2018.12.034.
   Google Scholar
• Miller BC, Sen DR, Al Abosy R, Bi K, Virkud YV, LaFleur MW, Yates KB, Lako A, Felt K, Naik GS, et al. Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol [Internet]. 2019;20(3):326–36. doi:10.1038/s41590-019-0312-6.
   PubMed Web of Science ®Google Scholar
• Bruni D, Angell HK, Galon J. The immune contexture and immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer [Internet]. 2020;20(11):662–80. doi:10.1038/s41568-020-0285-7.
   PubMed Web of Science ®Google Scholar
• Veglia F, Hashimoto A, Dweep H, Sanseviero E, De Leo A, Tcyganov E, Kossenkov A, Mulligan C, Nam B, Masters G, et al. Analysis of classical neutrophils and polymorphonuclear myeloid-derived suppressor cells in cancer patients and tumor-bearing mice. J Exp Med [Internet]. 2021;218. http://www.ncbi.nlm.nih.gov/pubmed/33566112.
   PubMed Web of Science ®Google Scholar
• Patel S, Fu S, Mastio J, Dominguez GA, Purohit A, Kossenkov A, Lin C, Alicea-Torres K, Sehgal M, Nefedova Y, et al. Unique pattern of neutrophil migration and function during tumor progression. Nat Immunol [Internet]. 2018;19(11):1236–47. doi:10.1038/s41590-018-0229-5.
   PubMed Web of Science ®Google Scholar
• Hashimoto A, Sarker D, Reebye V, Jarvis S, Sodergren MH, Kossenkov A, Sanseviero E, Raulf N, Vasara J, Andrikakou P, et al. Upregulation of C/EBPα inhibits suppressive activity of myeloid cells and potentiates antitumor response in mice and patients with cancer. Clin Cancer Res [Internet]. 2021;27(21):5961–78. doi:10.1158/1078-0432.CCR-21-0986.
   PubMed Web of Science ®Google Scholar
• Motz GT, Coukos G. Deciphering and reversing tumor immune suppression. Immunity [Internet]. 2013;39(1):61–73. doi:10.1016/j.immuni.2013.07.005.
   PubMed Web of Science ®Google Scholar
• Schmittnaegel M, Rigamonti N, Kadioglu E, Cassará A, Wyser Rmili C, Kiialainen A, Kienast Y, Mueller H-J, Ooi C-H, Laoui D, et al. Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade. Sci Transl Med [Internet]. 2017;9. http://www.ncbi.nlm.nih.gov/pubmed/28404865.
   PubMed Web of Science ®Google Scholar
• Martinez-Usatorre A, Kadioglu E, Boivin G, Cianciaruso C, Guichard A, Torchia B, Zangger N, Nassiri S, Keklikoglou I, Schmittnaegel M, et al. Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models. Sci Transl Med [Internet]. 2021;13. http://www.ncbi.nlm.nih.gov/pubmed/34380768.
   PubMed Web of Science ®Google Scholar
• Gudipati V, Rydzek J, Doel-Perez I, Gonçalves VDR, Scharf L, Königsberger S, Lobner E, Kunert R, Einsele H, Stockinger H, et al. Inefficient CAR-proximal signaling blunts antigen sensitivity. Nat Immunol [Internet]. 2020;21(8):848–56. doi:10.1038/s41590-020-0719-0.
   PubMed Web of Science ®Google Scholar
• Davenport AJ, Cross RS, Watson KA, Liao Y, Shi W, Prince HM, Beavis PA, Trapani JA, Kershaw MH, Ritchie DS, et al. Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity. Proc Natl Acad Sci USA [internet]. 2018;115(9):E2068–76. doi:10.1073/pnas.1716266115.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell [Internet]. 2000;100(1):57–70. doi:10.1016/S0092-8674(00)81683-9.
   Web of Science ®Google Scholar
• Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov [Internet]. 2022;12(1):31–46. doi:10.1158/2159-8290.CD-21-1059.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell [Internet]. 2011;144(5):646–74. doi:10.1016/j.cell.2011.02.013.
   Google Scholar
• Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell [Internet]. 2012;21(3):309–22. doi:10.1016/j.ccr.2012.02.022.
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, Grob J-J, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med [Internet]. 2019;381(16):1535–46. doi:10.1056/NEJMoa1910836.
   PubMed Web of Science ®Google Scholar
• Hanahan D. Rethinking the war on cancer. Lancet (London, England [Internet]. 2014;383(9916):558–63. doi:10.1016/S0140-6736(13)62226-6.
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y, Kudo M, Breder V, Merle P, Kaseb AO, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med [Internet]. 2020;382(20):1894–905. doi:10.1056/NEJMoa1915745.
   PubMed Web of Science ®Google Scholar
• Ferrucci PF, Di Giacomo AM, Del Vecchio M, Atkinson V, Schmidt H, Schachter J, Queirolo P, Long GV, Stephens R, Svane IM, et al. KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma. J Immunother Cancer [Internet]. 2020;8. http://www.ncbi.nlm.nih.gov/pubmed/33361337.
   PubMed Web of Science ®Google Scholar
• Legut M, Dolton G, Mian AA, Ottmann OG, Sewell AK. CRISPR-Mediated TCR replacement generates superior anticancer transgenic T cells. Blood [Internet]. 2018;131:311–22. http://www.ncbi.nlm.nih.gov/pubmed/29122757.
   Google Scholar
• Whalley T, Dolton G, Brown PE, Wall A, Wooldridge L, van den Berg H, Fuller A, Hopkins JR, Crowther MD, Attaf M, et al. GPU-accelerated discovery of pathogen-derived molecular mimics of a T-cell insulin epitope. Front Immunol [Internet]. 2020;11:296. doi:10.3389/fimmu.2020.00296.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios CH, Morise M, Felip E, Andric Z, Geater S, et al. Atezolizumab for first-line treatment of PD-L1–Selected patients with NSCLC. N Engl J Med [Internet]. 2020;383(14):1328–39. doi:10.1056/NEJMoa1917346.
   PubMed Web of Science ®Google Scholar
• Simoni Y, Becht E, Fehlings M, Loh CY, Koo S, Teng KWW, Yeong JPS, Nahar R, Zhang T, Kared H, et al. Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature [Internet]. 2018;557(7706):575–79. doi:10.1038/s41586-018-0130-2.
   Google Scholar
• Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, Zahurak M, Yang SC, Jones DR, Broderick S, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med [Internet]. 2018;378(21):1976–86. doi:10.1056/NEJMoa1716078.
   PubMed Web of Science ®Google Scholar
• Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson SJ, et al. Neoadjuvant Nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med [Internet]. 2022;386(21):1973–85. doi:10.1056/NEJMoa2202170.
   PubMed Web of Science ®Google Scholar
• Caushi JX, Zhang J, Ji Z, Vaghasia A, Zhang B, Hsiue E-C, Mog BJ, Hou W, Justesen S, Blosser R, et al. Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. Nature [Internet]. 2021;596(7870):126–32. doi:10.1038/s41586-021-03752-4.
   Google Scholar
• Zhang J, Ji Z, Caushi JX, El Asmar M, Anagnostou V, Cottrell TR, Chan HY, Suri P, Guo H, Merghoub T, et al. Compartmental analysis of T-cell clonal dynamics as a function of pathologic response to neoadjuvant PD-1 blockade in resectable non–small cell lung cancer. Clin Cancer Res [Internet]. 2020;26(6):1327–37. doi:10.1158/1078-0432.CCR-19-2931.
   PubMed Web of Science ®Google Scholar
• Andersen MH. The balance players of the adaptive immune system. Cancer Res [Internet]. 2018;78(6):1379–82. doi:10.1158/0008-5472.CAN-17-3607.
   PubMed Web of Science ®Google Scholar
• Sørensen RB, Hadrup SR, Svane IM, Hjortsø MC, Thor Straten P, Andersen MH. Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators. Blood [Internet]. 2011;117(7):2200–10. doi:10.1182/blood-2010-06-288498.
   Google Scholar
• Iversen TZ, Engell-Noerregaard L, Ellebaek E, Andersen R, Larsen SK, Bjoern J, Zeyher C, Gouttefangeas C, Thomsen BM, Holm B, et al. Long-Lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase. Clin Cancer Res [Internet]. 2014;20(1):221–32. doi:10.1158/1078-0432.CCR-13-1560.
   PubMed Web of Science ®Google Scholar
• Munir S, Andersen GH, Ö M, Donia M, Frøsig TM, Larsen SK, Klausen TW, Svane IM, Andersen MH. HLA-Restricted CTL that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients. Cancer Res [Internet]. 2013;73(6):1764–76. doi:10.1158/0008-5472.CAN-12-3507.
   PubMed Web of Science ®Google Scholar
• Jørgensen NG, Klausen U, Grauslund JH, Helleberg C, Aagaard TG, Do TH, Ahmad SM, Olsen LR, Klausen TW, Breinholt MF, et al. Peptide vaccination against PD-L1 with IO103 a novel immune modulatory vaccine in multiple myeloma: a phase i first-in-human trial. Front Immunol [Internet]. 2020;11:595035. doi:10.3389/fimmu.2020.595035.
   PubMed Web of Science ®Google Scholar
• Dey S, Sutanto-Ward E, Kopp KL, DuHadaway J, Mondal A, Ghaban D, Lecoq I, Zocca M-B, Merlo LMF, Mandik-Nayak L, et al. Peptide vaccination directed against IDO1-expressing immune cells elicits CD8+ and CD4+ T-cell-mediated antitumor immunity and enhanced anti-PD1 responses. J Immunother Cancer [Internet]. 2020;8. http://www.ncbi.nlm.nih.gov/pubmed/32690770.
   PubMed Web of Science ®Google Scholar
• Kjeldsen JW, Lorentzen CL, Martinenaite E, Ellebaek E, Donia M, Holmstroem RB, Klausen TW, Madsen CO, Ahmed SM, Weis-Banke SE, et al. A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma. Nat Med. 2021;27(12):2212–23. doi:10.1038/s41591-021-01544-x.
   PubMed Web of Science ®Google Scholar
• Aaboe Jørgensen M, Ugel S, Linder Hübbe M, Carretta M, Perez-Penco M, Weis-Banke SE, Martinenaite E, Kopp K, Chapellier M, Adamo A, et al. Arginase 1–based immune modulatory vaccines induce anticancer immunity and synergize with anti–PD-1 checkpoint blockade. Cancer Immunol Res [Internet]. 2021;9(11):1316–26. doi:10.1158/2326-6066.CIR-21-0280.
   PubMed Web of Science ®Google Scholar
• Dyck L, Lynch L. Cancer, obesity and immunometabolism - connecting the dots. Cancer Lett [Internet]. 2018;417:11–20. doi:10.1016/j.canlet.2017.12.019.
   PubMed Web of Science ®Google Scholar
• Dyck L, Prendeville H, Raverdeau M, Wilk MM, Loftus RM, Douglas A, McCormack J, Moran B, Wilkinson M, Mills EL, et al. Suppressive effects of the obese tumor microenvironment on CD8 T cell infiltration and effector function. J Exp Med [Internet]. 2022;219. http://www.ncbi.nlm.nih.gov/pubmed/35103755.
   Web of Science ®Google Scholar
• Michelet X, Dyck L, Hogan A, Loftus RM, Duquette D, Wei K, Beyaz S, Tavakkoli A, Foley C, Donnelly R, et al. Metabolic reprogramming of natural killer cells in obesity limits antitumor responses. Nat Immunol [Internet]. 2018;19(12):1330–40. doi:10.1038/s41590-018-0251-7.
   PubMed Web of Science ®Google Scholar
• McQuade JL, Daniel CR, Hess KR, Mak C, Wang DY, Rai RR, Park JJ, Haydu LE, Spencer C, Wongchenko M, et al. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol [Internet]. 2018;19:310–22. http://www.ncbi.nlm.nih.gov/pubmed/29449192.
   PubMed Web of Science ®Google Scholar
• DePeaux K, Delgoffe GM. Metabolic barriers to cancer immunotherapy. Nat Rev Immunol. 2021;21(12):785–97. doi:10.1038/s41577-021-00541-y.
   PubMed Web of Science ®Google Scholar
• Opitz CA, Somarribas Patterson LF, Mohapatra SR, Dewi DL, Sadik A, Platten M, Trump S. The therapeutic potential of targeting tryptophan catabolism in cancer. Br J Cancer [Internet]. 2020;122(1):30–44. doi:10.1038/s41416-019-0664-6.
   PubMed Web of Science ®Google Scholar
• Long GV, Dummer R, Hamid O, Gajewski TF, Caglevic C, Dalle S, Arance A, Carlino MS, Grob J-J, Kim TM, et al. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet Oncol [Internet]. 2019;20(8):1083–97. doi:10.1016/S1470-2045(19)30274-8.
   PubMed Web of Science ®Google Scholar
• Öztürk S, Kalter V, Roessner PM, Sunbul M, Seiffert M. IDO1-targeted therapy does not control disease development in the Eµ-TCL1 mouse model of chronic lymphocytic leukemia. Cancers (Basel) [Internet]. 2021;13. http://www.ncbi.nlm.nih.gov/pubmed/33920868.
   Web of Science ®Google Scholar
• Sadik A, Somarribas Patterson LF, Öztürk S, Mohapatra SR, Panitz V, Secker PF, Pfänder P, Loth S, Salem H, Prentzell MT, et al. IL4I1 is a metabolic immune checkpoint that activates the AHR and promotes tumor progression. Cell [Internet]. 2020;182(5):1252–70.e34. doi:10.1016/j.cell.2020.07.038.
   Google Scholar
• Hanna BS, Llaó-Cid L, Iskar M, Roessner PM, Klett LC, Wong JKL, Paul Y, Ioannou N, Öztürk S, Mack N, et al. Interleukin-10 receptor signaling promotes the maintenance of a PD-1int TCF-1+ CD8+ T cell population that sustains anti-tumor immunity. Immunity [Internet]. 2021;54(12):2825–41.e10. doi:10.1016/j.immuni.2021.11.004.
   PubMed Web of Science ®Google Scholar
• Martinez GJ, Pereira RM, Äijö T, Kim EY, Marangoni F, Pipkin ME, Togher S, Heissmeyer V, Zhang YC, Crotty S, et al. The transcription factor NFAT promotes exhaustion of activated CD8 + T cells. Immunity [Internet]. 2015;42(2):265–78. doi:10.1016/j.immuni.2015.01.006.
   PubMed Web of Science ®Google Scholar
• Neven B, Mamessier E, Bruneau J, Kaltenbach S, Kotlarz D, Suarez F, Masliah-Planchon J, Billot K, Canioni D, Frange P, et al. A Mendelian predisposition to B-cell lymphoma caused by IL-10R deficiency. Blood [Internet]. 2013;122(23):3713–22. doi:10.1182/blood-2013-06-508267.
   Google Scholar
• Saha T, Dash C, Jayabalan R, Khiste S, Kulkarni A, Kurmi K, Mondal J, Majumder PK, Bardia A, Jang HL, et al. Intercellular nanotubes mediate mitochondrial trafficking between cancer and immune cells. Nat Nanotechnol [Internet]. 2022;17(1):98–106. doi:10.1038/s41565-021-01000-4.
   PubMed Web of Science ®Google Scholar
• Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, Yizhak K, Sade-Feldman M, Blando J, Han G, et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature [Internet]. 2020;577(7791):549–55. doi:10.1038/s41586-019-1922-8.
   Google Scholar
• Cai R, Pan C, Ghasemigharagoz A, Todorov MI, Förstera B, Zhao S, Bhatia HS, Parra-Damas A, Mrowka L, Theodorou D, et al. Panoptic imaging of transparent mice reveals whole-body neuronal projections and skull–meninges connections. Nat Neurosci [Internet]. 2019;22(2):317–27. doi:10.1038/s41593-018-0301-3.
   PubMed Web of Science ®Google Scholar
• Pan C, Schoppe O, Parra-Damas A, Cai R, Todorov MI, Gondi G, von Neubeck B, Böğürcü-Seidel N, Seidel S, Sleiman K, et al. Deep learning reveals cancer metastasis and therapeutic antibody targeting in the entire body. Cell [Internet]. 2019;179(7):1661–76.e19. doi:10.1016/j.cell.2019.11.013.
   Google Scholar
• Bhatia HS, Brunner A-D, Rong Z, Mai H, Thielert M, Al-Maskari R, Paetzold JC, Kofler F, Todorov MI, Ali M, et al. Proteomics of spatially identified tissues in whole organs. bioRxiv [Internet]. 2021: 2021.11.02.466753. http://biorxiv.org/content/early/2021/11/04/2021.11.02.466753.abstract.
   Google Scholar
• Kolabas ZI, Kuemmerle LB, Perneczky R, Förstera B, Büttner M, Caliskan OS, Ali M, Rong Z, Mai H, Hummel S, et al. Multi-Omics and 3D-imaging reveal bone heterogeneity and unique calvaria cells in neuroinflammation. bioRxiv [Internet]. 2021:2021.12.24.473988. http://biorxiv.org/content/early/2021/12/25/2021.12.24.473988.abstract.
   Google Scholar
• Schraivogel D, Kuhn TM, Rauscher B, Rodríguez-Martínez M, Paulsen M, Owsley K, Middlebrook A, Tischer C, Ramasz B, Ordoñez-Rueda D, et al. High-speed fluorescence image–enabled cell sorting. Science [Internet]. 2022;375(6578):315–20. doi:10.1126/science.abj3013.
   Google Scholar
• Schraivogel D, Gschwind AR, Milbank JH, Leonce DR, Jakob P, Mathur L, Korbel JO, Merten CA, Velten L, Steinmetz LM. Targeted Perturb-seq enables genome-scale genetic screens in single cells. Nat Methods [Internet]. 2020;17(6):629–35. doi:10.1038/s41592-020-0837-5.
   PubMed Web of Science ®Google Scholar
• Voabil P, de Bruijn M, Roelofsen LM, Hendriks SH, Brokamp S, van den Braber M, Broeks A, Sanders J, Herzig P, Zippelius A, et al. An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer. Nat Med [Internet]. 2021;27(7):1250–61. doi:10.1038/s41591-021-01398-3.
   PubMed Web of Science ®Google Scholar
• Kaptein P, Jacoberger-Foissac C, Dimitriadis P, Voabil P, de Bruijn M, Brokamp S, Reijers I, Versluis J, Nallan G, Triscott H, et al. Addition of interleukin-2 overcomes resistance to neoadjuvant CTLA4 and PD1 blockade in ex vivo patient tumors. Sci Transl Med [Internet]. 2022;14(642):eabj9779. doi:10.1126/scitranslmed.abj9779.
   PubMed Web of Science ®Google Scholar
• Tarab-Ravski D, Stotsky-Oterin L, Peer D. Delivery strategies of RNA therapeutics to leukocytes. J Control Release [Internet]. 2022;342:362–71. doi:10.1016/j.jconrel.2022.01.016.
   PubMed Web of Science ®Google Scholar
• Kedmi R, Veiga N, Ramishetti S, Goldsmith M, Rosenblum D, Dammes N, Hazan-Halevy I, Nahary L, Leviatan-Ben-Arye S, Harlev M, et al. A modular platform for targeted RNAi therapeutics. Nat Nanotechnol [Internet]. 2018;13(3):214–19. doi:10.1038/s41565-017-0043-5.
   PubMed Web of Science ®Google Scholar
• Yong S-B, Ramishetti S, Goldsmith M, Diesendruck Y, Hazan-Halevy I, Chatterjee S, Somu Naidu G, Ezra A, Peer D. Dual-targeted lipid nanotherapeutic boost for chemo-immunotherapy of cancer. Adv Mater [Internet]. 2022;34(13):e2106350. doi:10.1002/adma.202106350.
   PubMed Web of Science ®Google Scholar
• Dammes N, Goldsmith M, Ramishetti S, Dearling JLJ, Veiga N, Packard AB, Peer D. Conformation-sensitive targeting of lipid nanoparticles for RNA therapeutics. Nat Nanotechnol [Internet]. 2021;16(9):1030–38. doi:10.1038/s41565-021-00928-x.
   PubMed Web of Science ®Google Scholar
• Rosenblum D, Gutkin A, Kedmi R, Ramishetti S, Veiga N, Jacobi AM, Schubert MS, Friedmann-Morvinski D, Cohen ZR, Behlke MA, et al. CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy. Sci Adv [Internet]. 2020;6. http://www.ncbi.nlm.nih.gov/pubmed/33208369.
   PubMed Web of Science ®Google Scholar
• Silva JM, Zupancic E, Vandermeulen G, Oliveira VG, Salgado A, Videira M, Gaspar M, Graca L, Préat V, Florindo HF. In vivo delivery of peptides and Toll-like receptor ligands by mannose-functionalized polymeric nanoparticles induces prophylactic and therapeutic anti-tumor immune responses in a melanoma model. J Control Release [Internet]. 2015;198:91–103. doi:10.1016/j.jconrel.2014.11.033.
   PubMed Web of Science ®Google Scholar
• Conniot J, Scomparin A, Peres C, Yeini E, Pozzi S, Matos AI, Kleiner R, Moura LIF, Zupančič E, Viana AS, et al. Immunization with mannosylated nanovaccines and inhibition of the immune-suppressing microenvironment sensitizes melanoma to immune checkpoint modulators. Nat Nanotechnol [Internet]. 2019;14(9):891–901. doi:10.1038/s41565-019-0512-0.
   PubMed Web of Science ®Google Scholar
• Corbet C, Feron O. Tumour acidosis: from the passenger to the driver’s seat. Nat Rev Cancer [Internet]. 2017;17(10):577–93. doi:10.1038/nrc.2017.77.
   PubMed Web of Science ®Google Scholar
• Bohn T, Rapp S, Luther N, Klein M, Bruehl T-J, Kojima N, Aranda Lopez P, Hahlbrock J, Muth S, Endo S, et al. Tumor immunoevasion via acidosis-dependent induction of regulatory tumor-associated macrophages. Nat Immunol [Internet]. 2018;19(12):1319–29. doi:10.1038/s41590-018-0226-8.
   PubMed Web of Science ®Google Scholar
• Seifert R, Lushington GH, Mou T-C, Gille A, Sprang SR. Inhibitors of membranous adenylyl cyclases. Trends Pharmacol Sci [Internet]. 2012;33(2):64–78. doi:10.1016/j.tips.2011.10.006.
   PubMed Web of Science ®Google Scholar
• Sekine H, Yamamoto M, Motohashi H. Tumors sweeten macrophages with acids. Nat Immunol [Internet]. 2018;19(12):1281–83. doi:10.1038/s41590-018-0258-0.
   PubMed Web of Science ®Google Scholar
• Johann K, Bohn T, Shahneh F, Luther N, Birke A, Jaurich H, Helm M, Klein M, Raker VK, Bopp T, et al. Therapeutic melanoma inhibition by local micelle-mediated cyclic nucleotide repression. Nat Commun [Internet]. 2021;12(1):5981. doi:10.1038/s41467-021-26269-w.
   PubMed Web of Science ®Google Scholar
• Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J [Internet]. 2021;11(4):69. doi:10.1038/s41408-021-00459-7.
   PubMed Web of Science ®Google Scholar
• Reinhard K, Rengstl B, Oehm P, Michel K, Billmeier A, Hayduk N, Klein O, Kuna K, Ouchan Y, Wöll S, et al. An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors. Science. 2020;367(6476):446–53. doi:10.1126/science.aay5967.
   PubMed Web of Science ®Google Scholar
• Ruggiero E, Carnevale E, Prodeus A, Magnani ZI, Camisa B, Merelli I, Politano C, Stasi L, Potenza A, Cianciotti BC, et al. CRISPR-Based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell function. Sci Transl Med [Internet]. 2022;14(631):eabg8027. doi:10.1126/scitranslmed.abg8027.
   PubMed Web of Science ®Google Scholar
• Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res [Internet]. 2009;15(17):5323–37. doi:10.1158/1078-0432.CCR-09-0737.
   PubMed Web of Science ®Google Scholar
• Gattinoni L, Speiser DE, Lichterfeld M, Bonini C. T memory stem cells in health and disease. Nat Med [Internet]. 2017;23(1):18–27. doi:10.1038/nm.4241.
   PubMed Web of Science ®Google Scholar
• Sabatino M, Hu J, Sommariva M, Gautam S, Fellowes V, Hocker JD, Dougherty S, Qin H, Klebanoff CA, Fry TJ, et al. Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies. Blood [Internet]. 2016;128:519–28. http://www.ncbi.nlm.nih.gov/pubmed/27226436.
   Google Scholar